Abstract
For the past several years, we have been engaged in developing a therapeutically effective strategy for disrupting gene function with reverse complementary, or so called `antisense', oligodeoxynucleotides (ODN). This pursuit has focused on finding appropriate diseases in which to apply this approach, and suitable gene targets. Of the genes that we have targeted for disruption using the antisense ODN strategy (Clevenger et al., 1995; Gewirtz and Calabretta, 1988; Ratajczak et al., 1992c; Small et al., 1994) one that has been of particular interest, and one where therapeutically motivated disruptions are now in clinical trial, is the myb gene (reviewed in Lyon et al., 1994). These trials involve treatment of human leukemias. These diseases are a logical choice for developing oncogene targeted therapies because of easy access to tissues, and the abundance of knowledge about the cell and molecular biology of these diseases. Nevertheless, as will be touched on below, other malignancies have also been examined as models for Myb targeted therapy with some surprisingly encouraging results. Finally, while we have focused our efforts on the ODN strategy, I will allude briefly to other strategies for disrupting Myb function with therapeutic intent.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anfossi G, Gewirtz AM and Calabretta B. . 1989 Proc. Natl. Acad. Sci. USA 86: 3379–3383.
Azrin MA, Mitchel JF, Bow LM, Pedersen CA, Cartun RW, Aretz TH, Waters DD and McKay RG. . 1997 Cathet. Cardiovasc. Diagn. 41: 232–240.
Barletta C, Pelicci PG, Kenyon LC, Smith SD and Dalla-Favera R. . 1987 Science 235: 1064–1067.
Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ and Jones RJ. . 1994 Blood 83: 2038–2044.
Bedi A, Zehnbauer BA, Collector MI, Barber JP, Zicha MS, Sharkis SJ and Jones RJ. . 1993 Blood 81: 2898–2902.
Biedenkapp H, Borgmeyer U, Sippel AE and Klempnauer KH. . 1988 Nature 335: 835–837.
Brown KE, Kindy MS and Sonenshein GE. . 1992 J. Biol. Chem. 267: 4625–4630.
Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB and et al. 1995 Proc. Natl. Acad. Sci. USA 92: 4051–4055.
Burk O, Mink S, Ringwald M and Klempnauer KH. . 1993 EMBO J. 12: 2027–2038.
Calabretta B and Gewirtz AM. . 1991 Crit. Rev. Oncog. 2: 187–194.
Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M and Gewirtz AM. . 1991 Proc. Natl. Acad. Sci. USA 88: 2351–2355.
Caracciolo D, Venturelli D, Valtieri M, Peschle C, Gewirtz AM and Calabretta B. . 1990 J. Clin. Invest. 85: 55–61.
Carson WE, Haldar S, Baiocchi RA, Croce CM and Caligiuri MA. . 1994 Proc. Natl. Acad. Sci. USA 91: 7553–7557.
Castier Y, Chemla E, Nierat J, Heudes D, Vasseur MA, Rajnoch C, Bruneval P, Carpentier A and Fabiani JN. . 1998 J. Cardiovasc. Surg. (Torino) 39: 1–7.
Chasty R, Whetton A and Lucas G. . 1996 Leuk. Res. 20: 391–395.
Clarke MF, Kukowska-Latallo JF, Westin E, Smith M and Prochownik EV. . 1988 Mol. Cell. Biol. 8: 884–892.
Clevenger CV, Ngo W, Sokol DL, Luger SM and Gewirtz AM. . 1995 J. Biol. Chem. 270: 13246–13253.
Cogswell JP, Cogswell PC, Kuehl WM, Cuddihy AM, Bender TM, Engelke U, Marcu KB and Ting JP. . 1993 Mol. Cell. Biol. 13: 2858–2869.
Dash AB, Orrico FC and Ness SA. . 1996 Genes Dev. 10: 1858–1869.
de Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T and Calabretta B. . 1997 Leukemia 11: 811–819.
de Fabritis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B and Mandelli F. . 1995 Leukemia 9: 662–664.
Dini PW, Eltman JT and Lipsick JS. . 1995 J. Virol. 69: 2515–2524.
Eckstein F. . 1996 Biochem. Soc. Trans. 24: 601–604.
Gewirtz AM, Anfossi G, Venturelli D, Valpreda S, Sims R and Calabretta B. . 1989 Science 245: 180–183.
Gewirtz AM and Calabretta B. . 1988 Science 242: 1303–1306.
Gewirtz AM, Luger S, Sokol D, Gowdin B, Stadtmauer E, Reccio A and Ratajczak MZ. (1996). . Blood 88, (Supplement 1): 270a.
Gewirtz AM, Sokol DL and Ratajczak MZ. . 1998 Blood 92: 712–736.
Giles RV, Spiller DG, Green JA, Clark RE and Tidd DM. . 1995 Blood 86: 744–754.
Graf T. . 1998 Curr. Biol. 8: R353–R355.
Gunther EJ, Havre PA, Gasparro FP and Glazer PM. . 1996 Photochem. Photobiol. 63: 207–212.
Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G and Gewirtz AM. . 1994 Proc. Natl. Acad. Sci. USA 91: 4499–4503.
James HA and Turner PC. . 1997 Methods Mol. Biol. 74: 1–9.
Jarvis TC, Alby LJ, Beaudry AA, Wincott FE, Beigelman L, McSwiggen JA, Usman N and Stinchcomb DT. . 1996 RNA 2: 419–428.
Kanei-Ishii C, MacMillan EM, Nomura T, Sarai A, Ramsay RG, Aimoto S, Ishii S and Gonda TJ. . 1992 Proc. Natl. Acad. Sci. USA 89: 3088–3092.
Kasono K, Piche A, Xiang J, Kim HG, Bilbao G, Johanning F, Nawrath M, Moelling K and Curiel DT. . 1998 Biochem. Biophys. Res. Commun. 251: 124–130.
Kowenz-Leutz E, Herr P, Niss K and Leutz A. . 1997 Cell 91: 185–195.
Ku DH, Wen SC, Engelhard A, Nicolaides NC, Lipson KE, Marino TA and Calabretta B. . 1993 J. Biol. Chem. 268: 2255–2259.
Kypreos KE, Nugent MA and Sonenshein GE. . 1998 Cell Growth Differ. 9: 723–730.
Lyman SD and Jacobsen SE. . 1998 Blood 91: 1101–1134.
Lyon J, Robinson C and Watson R. . 1994 Crit. Rev. Oncog. 5: 373–388.
McGahon A, Bissonnette R, Schmitt M, Cotter KM. Green DR and Cotter TG. . 1994 Blood 83: 1179–1187.
Melo JV. . 1996 Blood 88: 2375–2384.
Melotti P and Calabretta B. . 1994 J. Biol. Chem. 269: 25303–25309.
Melotti P and Calabretta B. . 1996 Proc. Natl. Acad. Sci. USA 93: 5313–5318.
Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, Pietryga DW, Scott Jr WJ and Potter SS. . 1991 Cell 65: 677–689.
Nakayama K, Yamamoto R, Ishii S and Nakauchi H. . 1993 Int. Immunol. 5: 817–824.
Ness SA, Kowenz-Leutz E, Casini T, Graf T and Leutz A. . 1993 Genes Dev. 7: 749–759.
Ness SA, Marknell A and Graf T. . 1989 Cell 59: 1115–1125.
Nomura N, Takahashi M, Matsui M, Ishii S, Date T, Sasamoto S and Ishizaki R. . 1988 Nucleic. Acids Res. 16: 11075–11089.
Pitsch RJ, Goodman GR, Minion DJ, Madura JAN, Fox PL and Graham LM. . 1996 Vasc. Surg. 23: 783–791.
Press RD, Reddy EP and Ewert DL. . 1994 Mol. Cell Biol. 14: 2278–2290.
Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P and Gewirtz AM. . 1992a Blood 79: 1956–1961.
Ratajczak MZ, Luger SM Hijiya N, Zhang J, Zon G and Gewirtz AM. . 1992b Proc. Natl. Acad. Sci. USA 89: 11823–11827.
Ratajczak MA, Luger SM, DeRiel K, Abrahm J, Calabretta B and Gewirtz AM. . 1992c Proc. Natl. Acad. Sci. USA 89: 1710–1714.
Ratajczak MA, Perrotti D, Melotti P, Powzaniuk M, Calabretta B, Onodera K, Kregenow DA, Machalinski B and Gewirtz AM. . 1998 Blood 91: 1934–1946.
Rosenberg RD. . 1993 Thromb. Haemost. 70: 10–16.
Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda TJ and Ishii S. . 1989 Proc. Natl. Acad. Sci. USA 86: 5758–5762.
Simons M, Ariyoshi H, Salzman EW and Rosenberg RD. . 1995 Am. J. Physiol. 268: C856–C868.
Simons M, Edelman ER, DeKeyser JL, Langer R and Rosenberg RD. . 1992 Nature 359: 67–70.
Simons M, Morgan KG, Parker C, Collins E and Rosenberg RD. . 1993 J. Biol. Chem. 268: 627–632.
Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM, et al. 1994 Proc. Natl. Acad. Sci. USA 91: 459–463.
Sullenger BA. . 1995 Appl. Biochem. Biotechnol. 54: 57–61.
Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM and Calabretta B. . 1991 Science 253: 562–565.
Taylor D, Badiani P and Weston K. . 1996 Genes Dev. 10: 2732–2744.
Thompson MA, Rosenthal MA, Ellis SL, Friend AJ, Zorbas MI, Whitehead RH and Ramsay RG. . 1998 Cancer Res. 58: 5168–5175.
Tomita A, Watanabe T, Kosugi H, Ohashi H, Uchida T, Kinoshita T, Mizutani S, Hotta T, Murate T, Seto M and Saito H. . 1998 Leukemia 12: 1422–1429.
Travali S, Ferber A, Reiss K, Sell C, Koniecki J, Calabretta B and Baserga R. . 1991a Oncogene 6: 887–894.
Travali S, Reiss K, Ferber A, Petralia S, Mercer WE, Calabretta B and Baserga R. . 1991b Mol. Cell. Biol. 11: 731–736.
Vandenbark GR, Chen Y, Friday E, Pavlik K, Anthony B, deCastro C and Kaufman RE. . 1996 Cell Growth Differ. 7: 1383–1392.
Vorbrueggen G, Kalkbrenner F, Guehmann S and Moelling K. . 1994 Nucleic Acids Res. 22: 2466–2475.
Wagner RW and Flanagan WM. . 1997 Mol. Med. Today 3: 31–38.
Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ, et al. 1997 Leuk. Lymphoma. 20: 67–76.
Yu H, Bauer B, Lipke GK, Phillips RKL and Van Zant G. . 1993 Blood 81: 373–384.
Acknowledgements
Supported in part by NIH grants RO1CA66731, PO1CA72765, and PO1DK52558-01. The editorial assistance of Elizabeth R Bien is gratefully acknowledged.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gewirtz, A. Myb targeted therapeutics for the treatment of human malignancies. Oncogene 18, 3056–3062 (1999). https://doi.org/10.1038/sj.onc.1202785
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202785
Keywords
This article is cited by
-
MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia
Leukemia (2015)
-
ESI Mass Spectrometric Exploration of Selective Recognition of G-Quadruplex in c-myb Oncogene Promoter Using a Novel Flexible Cyclic Polyamide
Journal of the American Society for Mass Spectrometry (2014)